Lynch syndrome

Its phenotypic and genotypic heterogeneity

Henry T. Lynch, Jane F. Lynch, Zoran Gatalica, C. Richard Boland

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

It is estimated that approximately 3-5% of all colorectal cancers may manifest the Lynch syndrome while its familial adenomatous polyposis counterpart accounts for less than 1% of the total colorectal cancer burden. Familial aggregation constitutes approximately 20% of all colorectal cancer occurrences. What does this mean to the geneticist, diagnostician, and ultimately the high-risk patient? Clearly, family history is the key, and when germline pathogenic mutations are identified within a family, one is then in the enviable position of providing a significant reduction in patients' cancer morbidity and mortality through highly-targeted screening and management. Confounders for each high-risk family will be the syndrome's phenotypic and genotypic heterogeneity, and therein it will be best comprehended through study of its natural history. In some cases the syndrome's complexity may be beyond the physician's knowledge, and help will then be available through referral to genetic counselors or centers of cancer genetics expertise. Finally, basic science and clinical studies on high-risk families harbor enormous opportunities to uncover etiology and pathogenesis which may ultimately translate into cancer prevention in both hereditary and sporadic forms of cancer.

Original languageEnglish
Pages (from-to)266-273
Number of pages8
JournalViszeralmedizin: Gastrointestinal Medicine and Surgery
Volume27
Issue number4
DOIs
StatePublished - Aug 2011

Fingerprint

Hereditary Nonpolyposis Colorectal Neoplasms
Colorectal Neoplasms
Neoplasms
Adenomatous Polyposis Coli
Germ-Line Mutation
Natural History
Referral and Consultation
Morbidity
Physicians
Mortality

All Science Journal Classification (ASJC) codes

  • Gastroenterology
  • Surgery

Cite this

Lynch syndrome : Its phenotypic and genotypic heterogeneity. / Lynch, Henry T.; Lynch, Jane F.; Gatalica, Zoran; Boland, C. Richard.

In: Viszeralmedizin: Gastrointestinal Medicine and Surgery, Vol. 27, No. 4, 08.2011, p. 266-273.

Research output: Contribution to journalArticle

Lynch, Henry T. ; Lynch, Jane F. ; Gatalica, Zoran ; Boland, C. Richard. / Lynch syndrome : Its phenotypic and genotypic heterogeneity. In: Viszeralmedizin: Gastrointestinal Medicine and Surgery. 2011 ; Vol. 27, No. 4. pp. 266-273.
@article{86965b78c52d47bcb77f381d725b6ea4,
title = "Lynch syndrome: Its phenotypic and genotypic heterogeneity",
abstract = "It is estimated that approximately 3-5{\%} of all colorectal cancers may manifest the Lynch syndrome while its familial adenomatous polyposis counterpart accounts for less than 1{\%} of the total colorectal cancer burden. Familial aggregation constitutes approximately 20{\%} of all colorectal cancer occurrences. What does this mean to the geneticist, diagnostician, and ultimately the high-risk patient? Clearly, family history is the key, and when germline pathogenic mutations are identified within a family, one is then in the enviable position of providing a significant reduction in patients' cancer morbidity and mortality through highly-targeted screening and management. Confounders for each high-risk family will be the syndrome's phenotypic and genotypic heterogeneity, and therein it will be best comprehended through study of its natural history. In some cases the syndrome's complexity may be beyond the physician's knowledge, and help will then be available through referral to genetic counselors or centers of cancer genetics expertise. Finally, basic science and clinical studies on high-risk families harbor enormous opportunities to uncover etiology and pathogenesis which may ultimately translate into cancer prevention in both hereditary and sporadic forms of cancer.",
author = "Lynch, {Henry T.} and Lynch, {Jane F.} and Zoran Gatalica and Boland, {C. Richard}",
year = "2011",
month = "8",
doi = "10.1159/000331186",
language = "English",
volume = "27",
pages = "266--273",
journal = "Visceral Medicine",
issn = "2297-4725",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Lynch syndrome

T2 - Its phenotypic and genotypic heterogeneity

AU - Lynch, Henry T.

AU - Lynch, Jane F.

AU - Gatalica, Zoran

AU - Boland, C. Richard

PY - 2011/8

Y1 - 2011/8

N2 - It is estimated that approximately 3-5% of all colorectal cancers may manifest the Lynch syndrome while its familial adenomatous polyposis counterpart accounts for less than 1% of the total colorectal cancer burden. Familial aggregation constitutes approximately 20% of all colorectal cancer occurrences. What does this mean to the geneticist, diagnostician, and ultimately the high-risk patient? Clearly, family history is the key, and when germline pathogenic mutations are identified within a family, one is then in the enviable position of providing a significant reduction in patients' cancer morbidity and mortality through highly-targeted screening and management. Confounders for each high-risk family will be the syndrome's phenotypic and genotypic heterogeneity, and therein it will be best comprehended through study of its natural history. In some cases the syndrome's complexity may be beyond the physician's knowledge, and help will then be available through referral to genetic counselors or centers of cancer genetics expertise. Finally, basic science and clinical studies on high-risk families harbor enormous opportunities to uncover etiology and pathogenesis which may ultimately translate into cancer prevention in both hereditary and sporadic forms of cancer.

AB - It is estimated that approximately 3-5% of all colorectal cancers may manifest the Lynch syndrome while its familial adenomatous polyposis counterpart accounts for less than 1% of the total colorectal cancer burden. Familial aggregation constitutes approximately 20% of all colorectal cancer occurrences. What does this mean to the geneticist, diagnostician, and ultimately the high-risk patient? Clearly, family history is the key, and when germline pathogenic mutations are identified within a family, one is then in the enviable position of providing a significant reduction in patients' cancer morbidity and mortality through highly-targeted screening and management. Confounders for each high-risk family will be the syndrome's phenotypic and genotypic heterogeneity, and therein it will be best comprehended through study of its natural history. In some cases the syndrome's complexity may be beyond the physician's knowledge, and help will then be available through referral to genetic counselors or centers of cancer genetics expertise. Finally, basic science and clinical studies on high-risk families harbor enormous opportunities to uncover etiology and pathogenesis which may ultimately translate into cancer prevention in both hereditary and sporadic forms of cancer.

UR - http://www.scopus.com/inward/record.url?scp=80053014148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053014148&partnerID=8YFLogxK

U2 - 10.1159/000331186

DO - 10.1159/000331186

M3 - Article

VL - 27

SP - 266

EP - 273

JO - Visceral Medicine

JF - Visceral Medicine

SN - 2297-4725

IS - 4

ER -